2023 World Conference on Lung Cancer (Posters)-EP12.01. Amivantamab: Prolonged Survivor in Post-TKI NSCLC with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutation (ex20ins)

EP12.01. Amivantamab: Prolonged Survivor in Post-TKI NSCLC with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutation (ex20ins) - PDF(Abstract)

Back to course

Pdf Summary

This case report discusses the efficacy of Amivantamab as a second-line treatment in a patient with EGFRex20ins non-small cell lung cancer (NSCLC). The EGFRex20ins mutation is a significant driver mutation in NSCLC, and this mutation is known to be less sensitive to approved EGFR tyrosine kinase inhibitors (TKI). The patient in this case was a 57-year-old non-smoking woman who was diagnosed with stage IV NSCLC with EGFRex20ins mutation.<br /><br />The patient initially received first-line treatment with Afatinib, but experienced progression of the disease in the pulmonary and lymph node levels. In March 2019, the patient started treatment with Amivantamab as part of a clinical trial. The patient experienced grade III dermatological toxicity in the form of paronychia, which led to a dose reduction of Amivantamab.<br /><br />Despite slow progression of the disease, the patient had a clinical response and continued with the study treatment. In May 2021, the patient received chest radiotherapy for a right parahilar lesion. The patient also underwent radiosurgery for a single brain lesion. However, in August 2021, the patient experienced massive right pleural effusion and pleural fluid analysis confirmed infiltration by adenocarcinoma of pulmonary origin.<br /><br />In May 2022, the patient had disease progression and loss of clinical benefit, leading to the discontinuation of Amivantamab. The patient then started a new line of treatment with Carboplatin plus Pemetrexed, which is ongoing with good tolerance and clinical benefit.<br /><br />Overall, this case report confirms the efficacy of Amivantamab as a second-line treatment for EGFRex20ins NSCLC, even for brain lesions. The treatment resulted in a prolonged survival with a good quality of life for the patient. This highlights the potential of Amivantamab as a targeted therapy for patients with this specific mutation in NSCLC.

Asset Subtitle

Andrés Aguilar

Meta Tag

Speaker Andrés Aguilar

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Amivantamab

second-line treatment

EGFRex20ins

non-small cell lung cancer

NSCLC

driver mutation

EGFR tyrosine kinase inhibitors

clinical trial

disease progression

Carboplatin plus Pemetrexed